GB-AF-017

GB-AF-017 is a preclinical therapeutic candidate developed by GAT Biosciences for the treatment of Inflammatory Bowel Disease (IBD). It is designed to target and inhibit Interleukin-23 (IL-23), a cytokine that plays a central role in the pathogenesis of chronic inflammatory conditions like Crohn's disease and ulcerative colitis. The candidate is part of GAT Biosciences' pipeline of gut-targeted therapies and is distinguished by its oral route of administration. While company documentation contains conflicting descriptors regarding its exact modality—referring to it as both an oral biologic (antibody/inhibitor) and an oral small molecule—its primary function is to neutralize IL-23 activity locally within the gastrointestinal tract to reduce inflammation while potentially minimizing systemic side effects.